Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

The genetics of low-density lipoprotein receptor-related protein 5 in bone: a story of extremes.

Balemans W, Van Hul W.

Endocrinology. 2007 Jun;148(6):2622-9. Epub 2007 Mar 29. Review.

PMID:
17395706
2.

LRP5 mutations in osteoporosis-pseudoglioma syndrome and high-bone-mass disorders.

Levasseur R, Lacombe D, de Vernejoul MC.

Joint Bone Spine. 2005 May;72(3):207-14. Review.

PMID:
15850991
3.

[Wnt signaling molecules related to osteoporosis].

Kubota T, Ozono K.

Clin Calcium. 2013 Jun;23(6):855-60. doi: CliCa1306855860. Review. Japanese.

PMID:
23719498
4.

[Cytokines in bone diseases. Wnt signaling and osteoporosis-pseudoglioma syndrome].

Ozono K.

Clin Calcium. 2010 Oct;20(10):1520-5. doi: CliCa101015201525. Review. Japanese.

PMID:
20890034
5.

[Regulation of bone metabolism by pathogenic mutations and polymorphism in the LRP5-Wnt signaling genes].

Urano T.

Nihon Rinsho. 2007 Nov 28;65 Suppl 9:95-100. Review. Japanese. No abstract available.

PMID:
18161089
6.

[Wnt-beta-catenin signaling in bone metabolism].

Urano T.

Clin Calcium. 2006 Jan;16(1):54-60. Review. Japanese.

PMID:
16397351
7.

The role of the Wnt signaling pathway in osteoblast commitment and differentiation.

Yavropoulou MP, Yovos JG.

Hormones (Athens). 2007 Oct-Dec;6(4):279-94. Review.

8.

Where Wnts went: the exploding field of Lrp5 and Lrp6 signaling in bone.

Williams BO, Insogna KL.

J Bone Miner Res. 2009 Feb;24(2):171-8. doi: 10.1359/jbmr.081235. Review.

9.

Genetic disorders of the LRP5-Wnt signalling pathway affecting the skeleton.

Koay MA, Brown MA.

Trends Mol Med. 2005 Mar;11(3):129-37. Review.

PMID:
15760771
10.

WNT signaling in bone homeostasis and disease: from human mutations to treatments.

Baron R, Kneissel M.

Nat Med. 2013 Feb;19(2):179-92. doi: 10.1038/nm.3074. Epub 2013 Feb 6. Review.

PMID:
23389618
11.

[Cytokines in bone diseases. Wnt signal and excessive bone formation].

Hosoi T.

Clin Calcium. 2010 Oct;20(10):1526-31. doi: CliCa101015261531. Review. Japanese.

PMID:
20890035
12.

[The role of Wnt/β-catenin pathway and LRP5 protein in metabolism of bone tissue and osteoporosis etiology].

Wolski H, Drwęska-Matelska N, Seremak-Mrozikiewicz A, Łowicki Z, Czerny B.

Ginekol Pol. 2015 Apr;86(4):311-4. Review. Polish.

PMID:
26117992
13.

Parameters of LRP5 from a structural and molecular perspective.

Johnson ML, Summerfield DT.

Crit Rev Eukaryot Gene Expr. 2005;15(3):229-42. Review.

PMID:
16390319
14.

Lrp5 and bone formation : A serotonin-dependent pathway.

Yadav VK, Ducy P.

Ann N Y Acad Sci. 2010 Mar;1192:103-9. doi: 10.1111/j.1749-6632.2009.05312.x. Review.

PMID:
20392224
15.

The high bone mass family--the role of Wnt/Lrp5 signaling in the regulation of bone mass.

Johnson ML.

J Musculoskelet Neuronal Interact. 2004 Jun;4(2):135-8. Review.

16.

Wnt signaling: a key regulator of bone mass.

Baron R, Rawadi G, Roman-Roman S.

Curr Top Dev Biol. 2006;76:103-27. Review.

PMID:
17118265
17.

Wnt signaling and osteoblastogenesis.

Bodine PV, Komm BS.

Rev Endocr Metab Disord. 2006 Jun;7(1-2):33-9. Review.

PMID:
16960757
18.

Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton.

Baron R, Rawadi G.

Endocrinology. 2007 Jun;148(6):2635-43. Epub 2007 Mar 29. Review.

PMID:
17395698
19.

The emerging role of serotonin (5-hydroxytryptamine) in the skeleton and its mediation of the skeletal effects of low-density lipoprotein receptor-related protein 5 (LRP5).

Warden SJ, Robling AG, Haney EM, Turner CH, Bliziotes MM.

Bone. 2010 Jan;46(1):4-12. doi: 10.1016/j.bone.2009.06.029. Epub 2009 Jul 8. Review.

20.

Common polymorphism in the LRP5 gene may increase the risk of bone fracture and osteoporosis.

Xu GY, Qiu Y, Mao HJ.

Biomed Res Int. 2014;2014:290531. doi: 10.1155/2014/290531. Epub 2014 Dec 14. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk